A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will
be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.